- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01050205
Diabetes Prevention Translation: the Healthy Lifestyle Project
Diabetes Prevention Translation Project: the Healthy Lifestyle Project
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Evidence that lifestyle intervention can prevent or delay the development of type 2 diabetes has been demonstrated in several clinical trials including a multi center clinical trial in the US, the Diabetes Prevention Program (DPP). The challenge for public health is to translate this promising and proven behavioral intervention utilized in the DPP research effort to the "real world", i.e., how to make it work in diverse communities in a variety of local settings at a reduced cost so that the maximal number of those at risk can benefit.
The purpose of this application is to test a framework for translation of the DPP that includes: 1) demonstration of a training model for community health care professionals that includes initial training, support, and supervision in the delivery of a diabetes prevention curriculum and the needed behavioral lifestyle materials both initially and over time; 2) evaluation of a more compact and flexible DPP intervention program administered to each participant in a version of his or her choice (standard face-to-face group format or a DVD version of the same lifestyle intervention program content). These lifestyle intervention programs will be carried out in three different community settings; i.e. a health care practice, a worksite, and local centers in the community dedicated to healthy aging for older adults. Lastly, the cost-effectiveness analyses of the GLB intervention program in each of the three community settings will be tested.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Screening Eligibility Criteria: Non-diabetic men and women from the specific study sites in the local area who are age 18 years and older at the time of screening with a BMI of at least 25 kg/m2 are eligible for screening.
Intervention Eligibility Criteria: Individuals attending screening who are found to have prediabetes AND/OR metabolic syndrome are eligible to participate in the intervention. Pre-diabetes is defined as having a fasting glucose >100 mg/dL and <126mg/dL. Metabolic syndrome is defined as having at least 3 of the 5 following risk factors:
- Waist circumference (>40 inches men, >35 inches women);
- Blood pressure >130 mmHg (systolic) or >85 mmHg (diastolic) OR history of diagnosed hypertension
- Low HDL level (<40mg/dL men, <50 mg/dL women)
- Elevated triglyceride level >150 mg/dL
- Fasting glucose >100mg/dL and <126mg/dL All individuals enrolled in the study should have at least 6th grade reading/writing ability.
Exclusion Criteria:
- Screening Exclusionary Criteria: Women who are currently (or within past 6-weeks) pregnant or lactating, or any individual planning to leave the area before the end of the effort will be considered ineligible to participate in the screening.
- Intervention Exclusionary Criteria: Exclusionary criterion for intervention is the same as for screening. In addition, individuals who are on metformin or are identified as having diabetes as a result of the screening are not eligible. Individuals who have recently (within the past 3 months) initiated or changed their dosage of any blood pressure or lipid medication will also be excluded as being on an unstable regimen will complicate the interpretation of any blood pressure or lipid effects of the intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Current Intervention
Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD).
Upon choosing, participants will be randomly assigned to "Current intervention" Arm in which case they will receive the intervention immediately.
|
Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity. GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings. |
Active Comparator: Delayed Intervention
Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD).
Upon choosing, participants will be randomly assigned to "Delayed Intervention" Arm in which case they will receive delayed intervention at 6 months.
|
Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity. GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Weight Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Weight was measured twice using a digital physician's scale (DETECTO® PD100) placed on a hard, flat surface.
Participants were asked to remove their shoes and stand in the middle of the scale with eyes straight forward and without touching any surface.
The participant was asked to step down from the scale between measures.
If the measures were more than 0.5 pounds apart, a third measure was taken.
Weight is reported in pounds.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Fasting Glucose Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the worksite and community/senior centers.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Fasting Insulin Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Venous blood draw: After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the worksite and community/senior centers.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Fasting Lipids (Total Cholesterol) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Venous blood draw: After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the work site and community/senior centers.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Fasting Lipids (Triglycerides) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Venous blood draw: After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the worksite and community/senior centers.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Fasting Lipids (HDL Cholesterol) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Venous blood draw: After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the worksite and community/senior centers.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Fasting Lipids (LDL Cholesterol) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Venous blood draw: After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the worksite and community/senior centers.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in A1c Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Venous blood draw: After the participant signed the consent, they were taken to the private phlebotomy area.
The participant sat in a stationary chair and placed their arm of choice for the blood draw flat on the table, on top of the BloodBloc pad.
The participant was asked the last time they had anything to eat or drink, including candy, mint, gum, cough drops, cough syrup, coffee or tea, (participants were expected to fast for 8-12 hours prior to their assessment visit).
If the participant had anything to eat or drink, other than water, the blood draw was rescheduled.
The fasting blood sample was analyzed by Quest Diagnostics™ laboratory for the worksite and community/senior centers.
A1c is a measure of glucose control over approximately an 8 to 12 week period.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Systolic Blood Pressure (BP) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Blood pressure was measured in the right arm with the participant seated comfortably with the right arm resting on a table.
All participants were asked to rest quietly with feet flat on the floor for five minutes.
Following the five minute wait, the radial pulse was measured in the right arm and pulse obliteration level was assessed.
The cuff was inflated to the peak inflation rate and the pressure released at a rate of 2mm/Hg per second.
First appearance and last heard (phase V) Korotkoff's sounds were utilized to determine systolic and diastolic blood pressure respectively.
The cuffed arm was then raised for 5 seconds after each inflation with a wait period of 30 seconds between each blood pressure reading.
Blood pressure was repeated twice with the average computed.
If it was not possible to measure blood pressure in the right arm, the left arm was utilized and noted in the participant record.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Waist Circumference Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
The participant was asked stand with feet together.
The waist was measured using a cloth measuring tape around the abdomen.
The midpoints were marked horizontally at midpoint between highest point of the iliac crest and lowest part of the costal margin in the mid-axillary line.
Both sides of the waist were marked using a cosmetic pencil.
The participant was asked to have arms at side and to breathe in, out and hold, and then the measurement was taken.
Waist measurement was recorded to the nearest quarter inch.
The measure was repeated twice.
If waist measures differ by more than one-half inch, a third measurement was recorded.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Self-reported Physical Activity Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
The Modifiable Activity Questionnaire (MAQ) was designed by Dr. Kriska.
It has been used to assess activity in a variety of populations and age groups over various time frames and was used to assess physical activity levels in the DPP.
The MAQ includes both a leisure and an occupational activity section since the homogeneity of energy expenditure related to both of these components of activity within many study populations cannot be assumed.
In addition, the MAQ was designed to be modified, based upon pilot testing, prior to its usage, in order to maximize the feasibility and appropriateness of the physical activity instrument to the population of interest.
The MAQ has been shown to be both reliable and valid (through comparisons with activity monitors, fitness (field) testing, and the doubly labeled water technique) in adults and adolescents alike.
The MAQ has been used to assess a variety of time frames from past year and past week to a lifetime of activity.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Changes in Diastolic Blood Pressure (BP) Between Baseline and Post-intervention (Assessed at 6 Months After Commencement of Intervention) Compared to Delayed Intervention Participants.
Time Frame: Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Blood pressure was measured in the right arm with the participant seated comfortably with the right arm resting on a table.
All participants were asked to rest quietly with feet flat on the floor for five minutes.
Following the five minute wait, the radial pulse was measured in the right arm and pulse obliteration level was assessed.
The cuff was inflated to the peak inflation rate and the pressure released at a rate of 2mm/Hg per second.
First appearance and last heard (phase V) Korotkoff's sounds were utilized to determine systolic and diastolic blood pressure respectively.
The cuffed arm was then raised for 5 seconds after each inflation with a wait period of 30 seconds between each blood pressure reading.
Blood pressure was repeated twice with the average computed.
If it was not possible to measure blood pressure in the right arm, the left arm was utilized and noted in the participant record.
|
Baseline and post-intervention (assessed at 6 months after commencement of intervention)
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Devaraj SM, Napoleone JM, Miller RG, Rockette-Wagner B, Arena VC, Mitchell-Miland C, Saad MB, Kriska AM. The role of Sociodemographic factors on goal achievement in a community-based diabetes prevention program behavioral lifestyle intervention. BMC Public Health. 2021 Oct 2;21(1):1783. doi: 10.1186/s12889-021-11844-z.
- Rockette-Wagner B, Miller RG, Eaglehouse YL, Arena VC, Kramer MK, Kriska AM. Leisure Sedentary Behavior Levels and Meeting Program Goals in a Community Lifestyle Intervention for Diabetes Prevention. J Phys Act Health. 2021 Jan 1;18(1):44-51. doi: 10.1123/jpah.2020-0052. Epub 2020 Dec 22.
- Schafer GL, Songer TJ, Arena VC, Kramer MK, Miller RG, Kriska AM. Participant food and activity costs in a translational Diabetes Prevention Program. Transl Behav Med. 2021 Mar 16;11(2):351-358. doi: 10.1093/tbm/ibaa031.
- Kramer MK, Vanderwood KK, Arena VC, Miller RG, Meehan R, Eaglehouse YL, Schafer G, Venditti EM, Kriska AM. Evaluation of a Diabetes Prevention Program Lifestyle Intervention in Older Adults: A Randomized Controlled Study in Three Senior/Community Centers of Varying Socioeconomic Status. Diabetes Educ. 2018 Apr;44(2):118-129. doi: 10.1177/0145721718759982. Epub 2018 Mar 7.
- Eaglehouse YL, Rockette-Wagner B, Kramer MK, Arena VC, Miller RG, Vanderwood KK, Kriska AM. Physical Activity Levels in a Community Lifestyle Intervention: A Randomized Trial. Transl J Am Coll Sports Med. 2016 Jun 1;1(5):45-51.
- Eaglehouse YL, Schafer GL, Arena VC, Kramer MK, Miller RG, Kriska AM. Impact of a community-based lifestyle intervention program on health-related quality of life. Qual Life Res. 2016 Aug;25(8):1903-12. doi: 10.1007/s11136-016-1240-7. Epub 2016 Feb 20.
- Vanderwood KK, Kramer MK, Miller RG, Arena VC, Kriska AM. Evaluation of non-invasive screening measures to identify individuals with prediabetes. Diabetes Res Clin Pract. 2015 Jan;107(1):194-201. doi: 10.1016/j.diabres.2014.06.003. Epub 2014 Jun 21.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO10010131
- R18DK081323-04 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Current Intervention
-
National University Health System, SingaporeRecruiting
-
Heinrich-Heine University, DuesseldorfUniversity Hospital, Essen; University Hospital Muenster; University of Cologne; University Hospital, Bonn and other collaboratorsRecruiting
-
Dartmouth-Hitchcock Medical CenterCompletedMultiple Sclerosis | Encephalitis | Seizures | Headache | Myasthenia Gravis | Meningitis | Parkinsonism | Spondylosis | Guillain-Barre Syndrome | Vestibular Disorder | Normal Pressure HydrocephalusUnited States
-
VA Office of Research and DevelopmentCompleted
-
Federal University of ParaíbaNot yet recruiting
-
Federal University of ParaíbaUnknown
-
Hospital Galdakao-UsansoloCompletedInflammatory Bowel Diseases | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Crohn Disease | Ulcerative Colitis | Pancreatitis, Acute | Esophagus CancerSpain
-
VA Office of Research and DevelopmentCompletedDiabetes | Foot UlcerUnited States
-
Oregon Health and Science UniversityNational Institutes of Health (NIH); Indiana UniversityRecruitingAsthma | Pulmonary Function | Wheezing | In Utero NicotineUnited States
-
Carlos III Health InstituteHealth Department of the Basque GovernmentCompleted